Lugano, Switzerland / Oxford, UK
The European Society for Medical Oncology (ESMO), the leading European organisation representing medical oncology professionals, today announced that Professor Jean-Charles Soria, MD, PhD will be the new Editor-in-Chief of Annals of Oncology as of January 2014.
Annals of Oncology is ESMO’s flagship scientific journal, established to keep medical oncologists at the cutting edge of new research developments. The journal is among the top twenty oncology journals worldwide and its impact factor is now 7.384.
“I am thrilled to have been selected for this position at such an exciting time in oncology and for such an important oncology journal, whose foundations have been deeply strengthened under Pr Vermorken’s leadership,” Soria said. “ESMO has been an important part of my professional career. I have been an ESMO member since 1997 and my past roles include, among others, Chair of the National Representatives Committee, with a seat on the Executive Board, and Scientific ESMO Co-chair of the EMCC meeting in 2011. My very first English peer-reviewed original manuscript was published in Annals of Oncology in 1997, when I was 26. As Editor-in-Chief of Annals of Oncology I will strive to increase the value of the journal for the Society members and more broadly for the whole readership.” .
Jean-Charles Soria, 42, is a medical oncologist with particular expertise in lung cancer. He was recently appointed Chair of the new Drug Development Department (DITEP) at Gustave Roussy Cancer Center in Paris, France. He has been Professor of Oncology at South Paris University since 2006 and heads a group of eight researchers at INSERM unit 981. Between 1996 and 2013 he has published over 330 papers and his H-index is currently 41. Soria received the Silver Medal from Paris Medical School in 1997 and gained a PhD in the fundamental basis of oncogenesis in 2001. He completed his training with a two-year post-doctoral fellowship in the department of thoracic, head and neck medical oncology at MD Anderson Cancer Center in Houston, USA, where he currently holds an Adjunct Professorship.
Soria’s top priority as Editor-in-Chief of Annals of Oncology will be to identify ways to push the impact factor even higher. He aims to increase the number of high-quality reviews and guidelines, including official ESMO Clinical Practice Guidelines, the reference standard for practicing clinicians. He also aims to attract more randomized trials -including the negative ones, and ad hoc editorials to dig into crucial issues facing medical oncology today. New sections will be developed to position the journal fully in the 21st century.
“Several key trends are influencing cancer care now and will transform oncology in the future,” Soria anticipated. The wave of biotechnology and bioinformatics, the availability of big data, new classifications of tumours are among the most visible changes, contributing to a robust growth in early drug trials, with a higher proportion of phase I/II to phase III studies. “Precision medicine is transforming cancer therapy, forcing us to rethink both how we manage the disease and how we teach our discipline. It’s an exciting time to work in and to report on,” Soria said. “With Annals of Oncology we will solicit articles on cutting-edge topics such as targets in oncology and novel immunomodulatory agents, reflecting the new molecular/genetic paradigm in oncology.”
“The profession of medical oncology is changing and scientific journals are evolving. ESMO and Annals of Oncology are at the top of their game and I will work to keep their position as leaders in the field, while raising their profile even further,” Soria concluded.
Notes to Editors
About the European Society for Medical Oncology
The European Society for Medical Oncology (ESMO) is the leading European professional organization committed to advancing the specialty of medical oncology and promoting a multidisciplinary approach to cancer treatment and care.
ESMO’s mission is to advance cancer care and cure through fostering and disseminating good science that leads to better medicine and determines best practice.
ESMO’s scientific journal, Annals of Oncology, ranks among the top clinical oncology journals worldwide. ESMO events are the meeting place in Europe for medical oncologists to update their knowledge, to network and to exchange ideas.
About Annals of Oncology
Annals of Oncology is devoted to the rapid publication of editorials, reviews, original articles and letters related to oncology, particularly medical oncology. Its character, however, is multidisciplinary, and contributions on clinically-oriented laboratory research, surgery and radiotherapy are assured by the presence of representatives of these disciplines among the Associate Editors and Editorial Board.
Annals of Oncology is the official journal of the European Society for Medical Oncology. Since 2008 the Journal is also affiliated with the Japanese Society of Medical Oncology.
Annals Of Oncology is covered by the following major indexing services:
- CAB Abstracts
- Current Contents® /Clinical Medicine
- Elsevier BIOBASE - Current Awareness in Biological Sciences (CABS)
- Journal Citation Reports /Science Edition
- Prous Science Integrity®
- Science Citation Index Expanded (SciSearch®)
- Science Citation Index®
Impact factor and ranking
Year | Impact Factor | Si: Oncology
2012 | 7.384 | 18 out of 196
2011 | 6.425 | 17 out of 19
2010 | 6.452 | 20 out of 184
2009 | 5.647 | 19 out of 165
2008 | 4.935 | 26 out of 141
2007 | 4.875 | 23 out of 132
2006 | 5.179 | 21 out of 127
This information is taken from the Journal Citation Reports, published annually as part of the Science Citation Index by ISI.